GlassScriptPhysician profile
Bruce Phillip Robinson
NPI 1700871829
$5,848.44
in general payments reported to CMS, 2019-2025
31 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $806 · 2021: $720 · 2022: $897 · 2023: $834 · 2024: $682 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.29 |
| Education | $161.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,325.42 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,023.06 | 2019-2025 | Tremfya |
| Genzyme Corporation | $422.81 | 2020-2025 | |
| Galderma Laboratories, L.P. | $380.70 | 2019-2024 | Aklief, Oracea, Twyneo |
| Almirall LLC | $344.16 | 2022-2025 | Seysara, Klisyri |
| Pfizer INC. | $286.73 | 2019-2025 | |
| Merz North America, INC. | $275.06 | 2019-2023 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $201.34 | 2020-2025 | Libtayo |
| Vyne Pharmaceuticals INC. | $179.31 | 2020-2021 | |
| Incyte Corporation | $150.68 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $122.07 | 2021-2025 | Ebglyss, Taltz |
| Epi Health, LLC | $110.45 | 2020-2022 | |
| Allergan, INC. | $95.84 | 2021-2022 | |
| Lnhc, INC | $92.62 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $87.57 | 2019-2025 | Anzupgo, Adbry |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $79.18 | 2021-2025 | Absorica Ld, Winlevi |
| Amgen INC. | $78.42 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $75.62 | 2019-2025 | |
| Dermavant Sciences, INC. | $75.27 | 2023-2024 | Vtama |
| Organon LLC | $72.99 | 2025 | Vtama |
| Journey Medical Corporation | $63.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $61.48 | 2023-2025 | Sotyktu |
| Dermira, INC. | $60.59 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $49.33 | 2024-2025 | Ycanth |
| Mayne Pharma Commercial LLC | $32.26 | 2019-2020 | |
| Botanix Sb INC | $23.52 | 2025 | Sofdra |
| Encore Dermatology INC. | $18.06 | 2019 | |
| Sebela Pharmaceuticals INC. | $16.27 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.56 | 2020 | |
| Arcutis Biotherapeutics, INC. | $14.10 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.